trending Market Intelligence /marketintelligence/en/news-insights/trending/uzkbyw128qxyqtclowucfa2 content esgSubNav
In This List

Mundipharma launches opioid dependence drug in EU, triggers €3M payment to Orexo

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Mundipharma launches opioid dependence drug in EU, triggers €3M payment to Orexo

Orexo AB (publ) said that its partner Mundipharma GmbH has launched opioid dependence treatment Zubsolv in the EU, triggering a milestone payment of €3 million from Mundipharma.

Germany-based Mundipharma gained the rights to Zubsolv outside the U.S. in a June 2016 agreement with the Swedish drugmaker.

The treatment is in the form of a tablet, containing buprenorphine and naloxone, that is placed under the tongue.

Recently, Mylan NV and Dr. Reddy's Laboratories Ltd. gained the U.S. Food and Drug Administration's approval to market generic versions of Indivior PLC's Suboxone film, also a combination of buprenorphine and naloxone.